Merrill raises price target on Repros on Androxal hopes

|About: Repros Therapeutics Inc. (RPRX)|By:, SA News Editor

Repros Therapeutics (RPRX) gets another vote of confidence (see Brean's commentary) from the sell-side, as BofA/ML raises the price target on the shares to $35 from $25.

The rationale: A derisked outlook for Androxal.

Shares +1.7% premarket

See previous Androxal coverage here